Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Exclusion Criteria

• •Histologically confirmed diagnosis of FL Gr 3b or transformed disease
• •Prior therapy with PI3K inhibitors
• •Ongoing or history of drug-induced pneumonitis
• •Known lymphomatous involvement of the central nervous system
• •Tested positive for or active viral infection with hepatitis B or C virus
• •Tested positive or active infection with human immunodeficiency virus
• •Tested positive, or active infection with human T-cell leukemia virus type 1
• •Any uncontrolled clinically significant illness
• •History of clinically significant cardiovascular abnormalities such as congestive heart failure
• •History of clinically significant gastrointestinal (GI) conditions
• •Females who are pregnant